Long-term disease control and safety with the anti-CCR4 antibody mogamulizumab: Post-hoc analyses from the MAVORIC trial of patients with previously treated cutaneous T-cell lymphoma.

Dermatol Ther

Multidisciplinary Cutaneous Lymphoma Program, Stanford University, Stanford, California, USA.

Published: August 2022

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539986	PMC
http://dx.doi.org/10.1111/dth.15634	DOI Listing

Publication Analysis

long-term disease

disease control

control safety

safety anti-ccr4

anti-ccr4 antibody

antibody mogamulizumab

mogamulizumab post-hoc

post-hoc analyses

analyses mavoric

mavoric trial

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!